Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial

Table 1

Significant changes in tumor reactive T cells as measured by ELISPOT in patients receiving DC-based immunotherapy for metastatic melanoma.

Change in relative number of spots	Week 4 versus week 0 (𝑁=42)
Increase 𝑃≤.05	7 (16.6%)
Decrease 𝑃≤.05	4 (9.5%)
No change 𝑃≥.05	31 (73.8%)